Trial Profile
Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: a Randomized H215O PET/CT Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms VANISH
- 30 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2013 New trial record